APTOSE’S TUSPETINIB TRIPLE DRUG THERAPY FEATURED AT THE 2025 ASH ANNUAL MEETING; HIGH RATE OF FRONTLINE CLINICAL RESPONSES CONTINUES ACROSS AML POPULATIONS

Reuters · 1d ago

Please log in to view news